购物车
全部删除
您的购物车当前为空
别名 PAR-4-AP (TFA), AY-NH2 (TFA)
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)) 是一种蛋白酶激活受体 4 (PAR-4) 激动剂,对 PAR-1 或 PAR-2 均无影响,其作用可被 PAR-4 拮抗剂阻断。

PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)) 是一种蛋白酶激活受体 4 (PAR-4) 激动剂,对 PAR-1 或 PAR-2 均无影响,其作用可被 PAR-4 拮抗剂阻断。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 269 | 现货 | |
| 5 mg | ¥ 852 | 现货 | |
| 10 mg | ¥ 1,430 | 现货 | |
| 25 mg | ¥ 2,380 | 现货 | |
| 50 mg | ¥ 3,460 | 现货 | |
| 100 mg | ¥ 4,720 | 现货 | |
| 200 mg | ¥ 6,370 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,390 | 现货 |
PAR-4 Agonist Peptide, amide TFA 相关产品
| 产品描述 | PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4), demonstrating specificity by not influencing PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist. |
| 体内活性 | SCID小鼠在0.04至0.1 mL膨胀水平下对结肠直肠膨胀(CRD)的腹部反应显著增强,其电肌图(EMG)反应强度分别增加了384%至132%(P<0.01; P<0.01; P<0.01; P<0.001),与其BALB/cBy对照组相比。PAR-4激活可有效逆转该过敏性(P<0.01, P<0.05; P<0.05; P<0.05)[1]。 |
| 别名 | PAR-4-AP (TFA), AY-NH2 (TFA) |
| 分子量 | 794.82 |
| 分子式 | C36H49F3N8O9 |
| CAS No. | 1228078-65-6 |
| Smiles | OC(=O)C(F)(F)F.C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O |
| 密度 | no data available |
| 颜色 | White |
| 物理性状 | Solid |
| Sequence | Ala-Tyr-Pro-Gly-Lys-Phe-NH2 |
| Sequence Short | AYPGKF-NH2 |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | H2O: 100 mg/mL (125.81 mM), Sonication is recommended. DMSO: 250 mg/mL (314.54 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.29 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容